PE-22-28
OtherAlso known as Spadin analog
Evidence tier
Limited published literature
1 publication over 9 years · trials not yet curated
- Researched since
- 2017
- Publications
- 1
- Mean purity
- —
- Vendors listing
- 1
No indexed vendor publishes certificate records for PE-22-28 that this index could read yet, so no purity comparison is possible.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2017 — 9 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
1 publication indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
1 of 1 listing vendor publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is PE-22-28?
A shortened synthetic analogue of spadin, studied preclinically as a TREK-1 potassium-channel inhibitor with antidepressant-like activity in animal models. The indexed literature under this exact name is very limited.
Studied in published research for depression and mood, as a TREK-1 channel inhibitor.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity — Frontiers in pharmacology (2017)
Peer-reviewed article indexed in PubMed, published in Frontiers in pharmacology (2017).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| American PeptidesISO/IEC 17025 | 86.5100% | $7.00 (100%) | 0 | — | — |
Certificate records
No certificate records are indexed. Either none are published, or those published could not be read without an account.